Form 4: Phyllis Yale Reports Acquisition of Bristol-Myers Squibb Deferred Share Units

Director Phyllis Yale reports the acquisition of deferred share units in Bristol-Myers Squibb, convertible to common stock upon future settlement.

Summary

• On March 31, 2024, Phyllis Yale, a director of Bristol-Myers Squibb, acquired 645.399 deferred share units.
• These units will convert into shares of common stock upon settlement, which occurs when Yale ceases to be a director or at a previously specified future date.
• The price per share is $54.23.
• Following the transaction, Yale beneficially owns 27,595.249 deferred share units, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a transaction. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The deferred share units will be converted into common stock upon settlement when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

This filing is a routine disclosure of a director's acquisition of deferred share units, a common form of compensation in publicly traded companies.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the potential future dilution upon conversion of the deferred share units.

Key Dates